SMi’s HPAPI 2018 Conference: Exclusive Interview Released with HPAPI Project Services
Justin Mason-Home is an organic chemist with extensive health, safety, environmental and chemical engineering experience in senior technical, legal and commercial aspects of the pharmaceutical, biochemical, chemical and other industries. He has held senior positions and worked globally in potent biopharmaceutical occupational health and safety global environmental consulting, board level positions in a biotechnology company and corporate environmental management. Justin has worked on multiple ADC projects and specialises in technical complex and strategic projects, including unique experience in managing sensitive highly potent and toxic biopharmaceutical compound matters.
SMi are excited to have interviewed Justin about his talk and career experience.
Below is a snapshot of the interview:
Q. How is your organisation involved in Highly Potent Active Pharmaceutical Ingredients?
A. "HPAPI Project Services Limited supports (bio)pharma companies in designing and delivering all the occupational health and safety elements in potent and high potent API projects on a scientific and systematic basis. Maybe the highest value area is in conceptual and detailed design as project capital costs are high and errors at this stage can be expensive and long-lived. Another key area is training, from the senior management strategic level, to the operational worker level."
Q. What technology or platform updates have really caught your eye in the past couple of years?
A. "The two that spring to mind are the real rise of flexible containment over the last 5+ years and the move to health-based exposure determinations used for cross-contamination management - a real (r)evolution and a long overdue move to a more scientific and systematic approach."
Q. What are the future challenges for the advancement of HPAPIs and what do you think are the biggest hindrances to achieving the utmost therapeutic potential of HPAPIs?
A. "I don’t think that there are any unsurmountable hindrances to developing the therapeutic potential of HPAPIs. Look at ADCs, highly potent APIs that previously were too toxic (including too narrow a therapeutic window) have been reborn when used in a much lower but highly targeted manner. You could not get a better example than Pfizer’s Mylotarg which has recently come back on the market after it was withdrawn in 2010 after patient toxicity concerns."
Q. Which markets are you looking to collaborate with in the future?
Check out the full interview, available in the download centre: www.highlypotentapi.com/pr4
Hear more from Justin at the HPAPI conference this April 2018, as he presents: 'Strategic Management of HPAPI projects.'
- Day 1 | @09:10
Topics will explore:
- Key stages of an HPAPI project
- Benefits of a Systematic and Scientific Approach
- Pot Pourri; Risk Assessment, QA and H&S conflicts, Pitfalls and more!
Plus... Attend a Workshop!
Justin will be hosting a half day post conference workshop on Wednesday 23rd May, where he will present 'Practical Steps for Delivering HPAPI Projects.'
Learn key HPAPI project elements, what factors are important and how to build information designed to underpin HPAPI project investments. All too often companies and their advisors, design and deliver HPAPI facilities based on “emotion” and guesswork. This workshop will try to ditch the emotion and provide a pathway to systematic and scientific project design.
For those looking to attend there is currently a £100 early-bird saving, ending March 29th.
Further information is available at: www.highlypotentapi.com/opr
SMi presents the 2nd Annual:
Highly Potent Active Pharmaceutical Ingredients (HPAPI)
Date: 21st – 22nd May 2018
Workshops: 23rd May 2018
Location: Holiday Inn Kensington Forum, London UK
For all media inquiries contact Pav Solanki on Tel: +44 (0)20 7827 6048 / Email: firstname.lastname@example.org
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Westminster Bridge Road
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release SMi’s HPAPI 2018 Conference: Exclusive Interview Released with HPAPI Project Services here
News-ID: 985959 • Views: 474
More Releases from SMi Group
Registration is now open for SMi’s Inaugural Medical Wearables for Biosensors …
SMi Reports: Registration is open for the Inaugural Medical Wearables for Biosensors Conference taking place October 25th – 26th in Boston, USA. As part of SMi’s leading series of medical device conferences, this year’s event will bring together expertise from individuals in multiple disciplines in the field of body-worn sensors and connected devices. The two-day conference will offer a series of presentations, through which you will gain insight into on-body devices for
Registration is now open for Pre-filled Syringes San Francisco Conference 2021
SMi Reports: Registration has opened for the 2nd annual Pre-Filled Syringes San Francisco taking place on 13th – 14th September. As part of SMi’s leading Injectables series, this year’s event will address the key drivers of the pre-filled syringes and combination products industry to give a comprehensive insight into the latest device innovations, regulatory updates and future insights for the coming year. Visit the event website to learn more and download
How a hard Brexit will impact the EU market and the effects of Parallel Trade pr …
SMi Reports: Exploring the challenges, practices and drivers in the aftermath of the transition for Parallel Trade. Join us at SMi’s 15th annual Parallel Trade Conference bringing together industry experts from leading experts to discuss the challenges and drivers of the industry, including the EU regulatory landscape and the impact of the FMD. Collaborate and share ideas of how a hard Brexit will impact the EU market and the effects of Parallel
Registration closing soon for SMi Group’s 14th Annual Border Security Conferen …
SMi Group reports: The Border Security conference hosted by SMi Group is taking place virtually in less than two weeks’ time. SMi Group's 14th annual Border Security conference will be closing in less than two weeks' time. For those interested in attending, important information about the event as well as the preliminary attendee list is released below. Registration is FREE for military and government personnel, and just £499 for commercial
More Releases for API
Terminating Twitter API Integrations
Thexyz Inc, the leading private email service that protects people and their data announces that a Twitter authentication apps developed by Thexyz will be discontinued and no longer supported. Thexyz focuses on security, privacy, freedom, and an open internet that respects the rights of individuals. It is a goal to work with organizations that share these values and discontinue support for services that do not. Thexyz has developed applications
Tagraxofusp - API Insight, 2018
Tagraxofusp, sold under the brand name of Elzonris, is an Interleukin 3 (IL-3) conjugated truncated diphtheria toxin. It is composed of catalytic and translocation domains of diphtheria toxin fused via Met-His linker to a full-length human IL-3. Download the sample report @ https://www.pharmaproff.com/request-sample/1168 Tagraxofusp was developed by Stemline Therapeutics Inc. and was approved in December 2018, as the first therapy for blastic plasmacytoid dendritic cell neoplasm. This drug achieved approval after
Cabozantinib- API Insight, 2018
Cabozantinib, sold under the brand name of Cabometyx and Cometriq, is used for the treatment of medullary thyroid cancer and a second line treatment for renal cell carcinoma. It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and also inhibits AXL and RET. Download the sample report @ https://www.pharmaproff.com/request-sample/1164 Discovered and developed by Exelixis Inc., its side-effects include increased liver enzymes, diarrhea, low calcium, mouth sores, decreased
Tyk API Management v2.3
After months working-out in the gym, the new version of Tyk is ready to flex its muscles. Tyk v2.3 is twice as fast, leaner, more extendable and is still available for FREE! London, United Kingdom 8th December, 2016. Tyk Technologies is pleased to announce the v2.3 release of Tyk, the popular open-source API Management platform. Tyk v2.3 builds upon the success of previous releases. The feedback and contributions from Tyk’s thriving open source community, as well as enterprise clients, drove
Telecom API Helps Application Developers to Integrate Various API Services
Telecom API market represents an overall Application Programming Interface (API) services provided by telecom carriers, service providers and aggregators to application developers in order to create mobile applications. Telecom API helps application developers to integrate various services such as payment, voice, SMS and WebRTC into their mobile application. This helps application developers to enhance their customer experience and market their mobile applications among end-users. Telecom API provides many benefits to
Biotech API Surging Worldwide
According to a new research report by RNCOS, entitled “Global Biotech API Market Analysis”, geographies across the world are showing insurgent growth in the biotech API Industry. The US occupied more than half of the share in the global market in 2011, and is the largest producer of biotech APIs. Western European countries occupy around 15% share globally among which, the UK is the largest producer of biotechnology-based APIs. The